STING/IFN Activation Promotes ANCA-Associated Vasculitis Progression

Save

Research presented in the Journal of Experimental Medicine shows that ANCA-associated vasculitis (AAV) may be propagated by pathogenic mechanisms triggering cGAS/STING/IRF3-dependent IFN-I release.

Autoimmune Disease Augments Cardiovascular Risk

Save

A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.

RheumNow Podcast –Rainbow Rheumatology (8.27.2022)

Save

Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.com

“Climate is what we expect, weather is what we get.” – Mark Twain

Olokizumab, another IL-6 Inhibitor for RA

Save

This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.

This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6 receptor.

Hyaluronic Acid Knee Injections Equivalent to Placebo

Save

In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.

Bullous Systemic Lupus Erythematosus

Save

Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).

As goes SLE, bullous disease typically affects women, especially those of African descent.

Weight Loss Slows Knee OA Progression

Save

Declines in body mass index (BMI) were linked with slower worsening of knee osteoarthritis (OA), according to data from three large longitudinal cohort studies.

Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis

Save

A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.

What to do with "no-shows"

Save

A current Medscape article on patient "no shows" in private medical practice examines the cause and approach to the problem.

The most common reason for no shows is lack of knowledge about the scheduled appointment. Here are other common causes of no-shows, and how to address the problem.

Managing JDM with Calcinosis

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

Melatonin Use Growing, Inappropriate & Potentially Unsafe

Save

With nearly one-third of adults, adolescents and children having sleep difficulties, many resort to using melatonin. JAMA reports substantial increases in the use of over-the-counter (OTC) melatonin, in all age groups. But is it effective, safe and warranted?

Rituximab Efficacy in Systemic Sclerosis

Save

The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.

Low Dose IL-2 Therapy in SLE

Save

A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE).

Favorable Pregnancy Outcomes in Spondyloarthritis

Save

Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature.

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA

Save

JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.

Black Adults Have a Higher Gout Risk

Save

In a cross-sectional study of US adults, gout was more prevalent in black adults compared to white adults; possibly explained by sex-specific dietary differences and social determinants of health and clinical factors. 

Global Mortality Rates for PsA, SpA and Colitis

Save

Global age-standardized mortality rate (ASMR) for 1000000 was for 0.13 for AS, 0.04 for PsA, 0.86 for CD and 0.76 for UC.

Hit Parade Review (8.12.2022)

Save

We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more. In what order should these items be discussed? This week the run down is based on popularity, measured by rheumatologist engagements on the website and social media.